ZVRA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -899.19% compared to Zevra Therapeutics's net margin of 11.99%. Zevra Therapeutics's return on equity of -159.89% beat Johnson & Johnson's return on equity of 20.88%.

Zevra Therapeutics has a consensus price target of --, signalling upside risk potential of 133.1%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.97%. Given that Zevra Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Zevra Therapeutics is more attractive than Johnson & Johnson.

Zevra Therapeutics has a beta of 1.972, which suggesting that the stock is 97.163% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.35% to investors and pays a quarterly dividend of $1.24 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics quarterly revenues are $3.7M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Zevra Therapeutics's net income of -$33.2M is lower than Johnson & Johnson's net income of $2.7B. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.91x versus 4.02x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -899.19% compared to Zevra Therapeutics's net margin of -11.17%. Zevra Therapeutics's return on equity of -159.89% beat Vanda Pharmaceuticals's return on equity of -3.02%.

Zevra Therapeutics has a consensus price target of --, signalling upside risk potential of 133.1%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $10.43 which suggests that it could grow by 122.81%. Given that Zevra Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Zevra Therapeutics is more attractive than Vanda Pharmaceuticals.

Zevra Therapeutics has a beta of 1.972, which suggesting that the stock is 97.163% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.283%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $3.7M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $47.7M. Zevra Therapeutics's net income of -$33.2M is lower than Vanda Pharmaceuticals's net income of -$5.3M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.91x versus 1.42x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -899.19% compared to Zevra Therapeutics's net margin of -29%. Zevra Therapeutics's return on equity of -159.89% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Zevra Therapeutics has a consensus price target of --, signalling upside risk potential of 133.1%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of -- which suggests that it could grow by 39.38%. Given that Zevra Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Zevra Therapeutics is more attractive than Xeris Biopharma Holdings.

Zevra Therapeutics has a beta of 1.972, which suggesting that the stock is 97.163% more volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 1.812, suggesting its more volatile than the S&P 500 by 81.233%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $3.7M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $54.3M. Zevra Therapeutics's net income of -$33.2M is lower than Xeris Biopharma Holdings's net income of -$15.7M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.91x versus 2.63x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of -899.19% compared to Zevra Therapeutics's net margin of 28.56%. Zevra Therapeutics's return on equity of -159.89% beat Zoetis's return on equity of 48%.

Zevra Therapeutics has a consensus price target of --, signalling upside risk potential of 133.1%. On the other hand Zoetis has an analysts' consensus of $214.22 which suggests that it could grow by 30.4%. Given that Zevra Therapeutics has higher upside potential than Zoetis, analysts believe Zevra Therapeutics is more attractive than Zoetis.

Zevra Therapeutics has a beta of 1.972, which suggesting that the stock is 97.163% more volatile than S&P 500. In comparison Zoetis has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.103%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.05% to investors and pays a quarterly dividend of $0.43 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics quarterly revenues are $3.7M, which are smaller than Zoetis quarterly revenues of $2.4B. Zevra Therapeutics's net income of -$33.2M is lower than Zoetis's net income of $682M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Zoetis's PE ratio is 30.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.91x versus 8.20x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.